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Hyaluronidase is a goat testicular protein that hydrolyzes hyaluronic acid, a structural component of the intercellular matrix. It is commonly used 
as a spreading factor to improve the diffusion of drugs, including local anesthetics and chemotherapeutics. We experienced a 55-yr-old female 
with generalized urticaria that developed within 1 hr after the epidural injection of hyaluronidase. She had a history of allergic rhinitis, and had 
suffered from post-herpetic neuralgia and a herniated disc for several years. To relieve her pain, she had been given epidural injections consisting 
of mepivacaine hydrochloride, triamcinolone acetonide, and morphine sulfate biweekly for one year. Hyaluronidase had been administered several 
times with these drugs before this episode of generalized urticaria. Skin prick testing showed a positive response to 1,500 IU/mL of hyaluronidase 
extract, as compared to histamine. The patient’s serum hyaluronidase-specific IgE level, determined using an enzyme-linked immunosorbent assay 
(ELISA), was markedly elevated, as compared to unexposed healthy controls. An IgE immunoblot analysis using hyaluronidase extract and the 
patient’s serum showed IgE binding components at 31 and 21 kDa, whereas no corresponding IgE binding component was found in healthy 
controls. An ELISA inhibition test showed significant, dose-dependent inhibition with the serial addition of hyaluronidase extract. This is the first 
case of an IgE-medicated allergic reaction to goat (Naemorhedus goral raddenus) hyaluronidase, demonstrated by skin testing and a specific IgE 
and immunoblot assay.
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INTRODUCTION
Hyaluronidase is an enzyme with a temporary, reversible de-
polymerizing action on hyaluronic acid present in the intracel-
lular matrix of connective tissue. It is commonly used as a 
spreading factor to improve the diffusion of drugs in anesthesi-
ology, dermatology, plastic surgery, and chemotherapeutics.
1,2 
Occasional allergic reactions associated with hyaluronidase 
have been reported. The majority of cases have involved imme-
diate hypersensitivity, such as anaphylaxis or angioedema.
3,4 
Rarely, delayed hypersensitivity has been reported after a perib-
ulbar block with a combination of hyaluronidase and anesthet-
ic in the ophthalmology literature.
5 We identified a case of acute 
generalized urticaria caused by the injection of hyaluronidase.
CASE REPORT
A 55-yr-old woman developed generalized urticaria 1 hour af-
ter the epidural injection of 1,500 IU of hyaluronidase (H-lase
®, 
Gunil, Seoul, Korea). She had atopy and showed a positive re-
sponse to house dust mites on skin prick test. She had previ-
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ously been diagnosed with allergic rhinitis, and had suffered 
from post-herpetic neuralgia and a herniated disc for several 
years. To relieve her pain, she had been given epidural injec-
tions consisting of 200 mg of mepivacaine hydrochloride (Mev-
an
®, Hanlim, Seoul, Korea), 40 mg of triamcinolone acetonide 
(Triam
®, Shinpung, Seoul, Korea), and 0.5 mg of morphine sul-
fate (Hanlim, Seoul, Korea) biweekly for one year. Hyaluroni-
dase had been administered several times before this episode 
of generalized urticaria, implying that sensitization had taken 
place. Since she had previously been given the above-men-
tioned drugs without problem and had no history of allergy to 
anesthetics, hyaluronidase was suspected as the causative 
drug. Skin prick test showed a positive response to 1,500 IU/mL 
of hyaluronidase extract compared to that of histamine (6×4/ 
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20×19 vs 4×3/16×15 mm).
6,7 The patient’s serum specific IgE 
antibodies to hyaluronidase were measured using an enzyme-
linked immunosorbent assay (ELISA), which revealed marked 
elevation compared to 14 unexposed healthy controls. The pos-
itive cutoff value was determined as the mean plus three stan-
dard deviations of the absorbance values for the normal con-
trols. An IgE immunoblot analysis using hyaluronidase extract 
and the patient’s serum showed IgE binding components at 31 
and 21 kDa, whereas no corresponding IgE binding component 
was found in 14 healthy controls (Fig. 1). After treatment with 
systemic oral steroid and antihistamines, her symptoms im-
proved substantially. Subsequently, mepivacaine alone has 
been administered for the nerve block.
DISCUSSION
Allergic reactions to hyaluronidase are not common. The esti-
mated incidence in an ophthalmic surgery department was ap-
proximately 0.1%.
6 As hyaluronidase is used in various medical 
fields, reports on allergy to hyaluronidase have been increasing 
over the last decade. Recently, the epidural injection of hyal-
uronidase has been performed more commonly in pain clin-
ics.
8,9
In previous reports, the hyaluronidase was usually adminis-
tered via local injection for peribulbar block in cataract surgery 
4,6 or via an intravenous route as an additive to a chemothera-
peutic drug in oncology.
1,3 The initial manifestations were influ-
enced by the route of administration: when given at a local site, 
localized angioedema or urticaria developed;
6,10,11 when given 
intravenously, most patients presented with anaphylactic 
shock, urticaria, or dyspnea.
3 Our patient was administered hy-
aluronidase via an intrathecal route at a relatively high dose of 
1,500 IU. No previous allergic reactions induced by intrathecal 
hyaluronidase administration have been reported.
The dosage of the drug is associated with the allergic reactions 
to hyaluronidase. With local reactions, the dose administered 
ranged from 100 to 150 IU. Patients with systemic reactions   
had received a single intravenous dose ranging from 1,500 to 
200,000 IU. However, the cumulative dose is not related to clini-
cal manifestations.
3 Most of the patients with hyaluronidase al-
lergy had a positive skin prick test or intradermal test.
6,10 When 
hyaluronidase is supposed to be administrated at high-dose 
hyaluronidase via intravenous or intrathecal routes, skin prick 
test could be a useful way to predict systemic allergic reactions.
Hyaluronidase as a medical product is derived from the testes 
of cows, goats, and sheep. Of these, goat-derived hyaluronidase 
is the most widely prescribed product in Korea. In addition, hy-
aluronidase is present in bee and ant venoms, invasive nema-
todes, and group B Streptococci.
1 To evaluate the cross-reactivity 
between hyaluronidase and honeybee and yellow jacket ven-
oms (Phadia, Uppsala, Sweden), ELISA inhibition tests were 
performed. The test with hyaluronidase extract showed signifi-
cant dose-dependent inhibition, whereas no inhibition was 
seen with the bee venom allergens.
 In conclusion, the patient in this case developed generalized 
urticaria immediately after exposure to goat-derived hyaluroni-
dase. A positive skin prick test and high serum-specific IgE to 
hyaluronidase were noted. Moreover, two IgE-binding compo-
nents were identified on IgE immunoblot assay, indicating that 
hyaluronidase derived from the goat (Naemorhedus goral rad-
denus) can induce an IgE-mediated allergic reaction in exposed 
subjects.
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Fig. 1. Hyaluronidase-specific IgE serum levels, as determined using an en-
zyme-linked immunosorbent assay (ELISA), in the sensitized patient and 14 
normal controls (A). Sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and IgE immunoblot analysis of hyaluronidase (B) in serum 
from the sensitized patient (P), a healthy control (N), and a buffer control (B).
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